The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.

@article{Kappers2011TheVE,
  title={The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.},
  author={Mari{\"e}tte H W Kappers and Frank M. M. Smedts and Thomas Horn and Joep H. M. van Esch and Stefan Sleijfer and Frank Leijten and Sebastiaan Wesseling and Helena Strevens and Alexander H Jan Danser and Anton H. van den Meiracker},
  journal={Hypertension},
  year={2011},
  volume={58 2},
  pages={
          295-302
        }
}
Angiogenesis inhibition is an established treatment for several tumor types. Unfortunately, this therapy is associated with adverse effects, including hypertension and renal toxicity, referred to as "preeclampsia." Recently, we demonstrated in patients and in rats that the multitarget tyrosine kinase inhibitor sunitinib induces a rise in blood pressure (BP), renal dysfunction, and proteinuria associated with activation of the endothelin system. In the current study we investigated the effects… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 62 CITATIONS, ESTIMATED 50% COVERAGE

Management of VEGF-Targeted Therapy-Induced Hypertension

Stefano Caletti, Anna Maria Paini, +6 authors Damiano Rizzoni
  • Current Hypertension Reports
  • 2018

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.

Effects of angiotensin II and its metabolites in the rat coronary vascular bed : Is angiotensin III the preferred ligand of the angiotensin AT ( 2 ) receptor ?

van Esch JHM, CR Oosterveer, WW Batenburg, R vanVeghel, Danser AHJ
  • Eur J Pharmacol .
  • 2008